- Diverchim, a French drug substance CDMO, has acquired Innoverda, a leader in electrochemical process development.
- The acquisition strengthens Diverchim’s capabilities in sustainable and eco-friendly drug substance development, combining both companies’ expertise in electrochemistry.
Diverchim, a renowned French Contract Development and Manufacturing Organization (CDMO), has announced the acquisition of Innoverda, a Contract Research Organization (CRO) known for its electrochemical process solutions. The deal merges Diverchim’s strengths in drug substance development with Innoverda’s expertise in electrochemical technologies, particularly electrosynthesis and electrodialysis.
Innoverda, founded in 2017, has positioned itself as a European leader in using electrochemical processes to replace traditional chemical reactions that often rely on toxic reagents and high energy consumption. The company’s solutions provide a more sustainable and efficient approach to manufacturing across various sectors, including pharmaceuticals, fine chemistry, and bioeconomy. This acquisition marks a strategic move for Diverchim, bringing together both companies’ capabilities to offer greener, more efficient manufacturing solutions.
The acquisition also opens new opportunities for Innoverda, expanding its service offerings to include scale-up and cGMP manufacturing. This will enable the company to better support clients with integrated solutions ranging from process development to industrial production. For Diverchim, the integration of Innoverda’s advanced electrochemical technologies positions the company as the only CDMO with expertise in electrochemistry, providing customers with cutting-edge solutions for sustainable drug substance development.
François Macarez, CEO of Diverchim, highlighted the strategic value of the acquisition, stating, “The acquisition of Innoverda adds a powerful new dimension to our expertise, positioning Diverchim as the only CDMO with proven skills in electrochemistry. We are confident that our customers will greatly benefit from these innovative and environmentally friendly technologies.”
Irene Erdelmeier, Founder of Innoverda, expressed her excitement about the partnership, noting, “We are thrilled about this new chapter, which will allow us to expand Innoverda’s capabilities and create new opportunities for the development of electrochemical solutions in the pharmaceutical industry.”